|
|
|
| home > white papers > Accelerating the Time from DNA to Material - Merck |
|
|
 WHITE PAPERS |
|
Merck
|
|
Accelerating the Time from DNA to Material
|
|
Cell line development is a critical step in upstream process development
for monoclonal antibodies (mAbs). Unfortunately, the search for the
bestproducing clone can be labor- and resource-intensive and is often
compared with looking for a needle in a haystack. Cells must first be
engineered to produce the biologic of interest and the cell line
generated from a high producing clone must deliver a sufficiently high
titer to support clinical studies, and ultimately commercialization of
the therapeutic.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Advanced Clinical Continues Global Expansion Into Asia-Pacific With New Office in Australia
Advanced Clinical, a global clinical research services organization,
continues to build upon its growth strategy in the Asia-Pacific (APAC)
region with the opening of a new office in Sydney, Australia.
More info >> |
|
 |
White Papers |
 |
|
|
|
